Priority Medicines for Europe and the World Project

"A Public Health Approach to Innovation"

 

Appendices to Section 8.2

Approach to the Valuation and Pricing of Future Medicines

8.2.1    Access to high cost drugs in Australia [pdf 55KB]

 

8.2.2    The Pharmaceutical Industry -- Prices and Progress, F.M. Scherer, Ph.D.   

 

8.2.3    The Pharmaceutical industry as a medicines provider [pdf 94KB] 
Reprinted with permission from Elsevier. (Lancet 2002;360, 16 November:1590-1595). The Lancet Homepage is at http://www.thelancet.com

 

8.2.4    Differential pricing of drugs: a role for cost-effectiveness analysis? [pdf 655KB]
Reprinted with permission from Elsevier. (Lancet 2002;359, 15 June:2105-2107).

 

8.2.5    EFPIA Comments on new approaches to promoting innovation [word 39KB]

 

8.2.6    Dossiers Statistics 2004 [ppt 655KB]

 

8.2.7    Executive Summary 
(The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis) [pdf 133KB]

 

8.2.8    The Economic Impact of Pharmaceutical Parallel Trade in European Union Member States: A Stakeholder Analysis [pdf 4.4MB] (http://www.lse.ac.uk/collections/LSEHealthAndSocialCare/)

 

8.2.9   Benefits to Payers and Patients From Parallel Trade, York Health Economics Consortium [pdf 285KB]

 

8.2.10 European Parliament Hearings -- Answers to questionnaire for commissioner designate [pdf 156KB]

 

8.2.11 Trading Up: How Much Should Poor Countries Pay to Support Pharmaceutical Innovation? Center for Global Development Brief By Jean O. Lanjouw and William Jack November, 2004 [pdf 112KB]